Novel Detection System for Lung Cancer Curative Effect Monitoring
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02666755|
Recruitment Status : Unknown
Verified January 2016 by Jian Zhang, Air Force Military Medical University, China.
Recruitment status was: Not yet recruiting
First Posted : January 28, 2016
Last Update Posted : January 29, 2016
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||160 participants|
|Official Title:||Novel Detection System for Detecting Epidermal Growth Factor Receptor Mutation in Plasma in Non-small Cell Lung Cancer|
|Study Start Date :||January 2016|
|Estimated Primary Completion Date :||January 2018|
|Estimated Study Completion Date :||April 2018|
- sensitivity [ Time Frame: 2 years ]comparing with results in tissues, tne investigators can get the sensitivity of results in plasma for Epidermal Growth Factor Receptor mutation in Non-small cell lung cancer.
- specificity [ Time Frame: 2 years ]comparing with results in tissues, the investigators can get the specificity of results in plasma for Epidermal Growth Factor Receptor mutation in Non-small cell lung cancer.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02666755
|Contact: Ning Chang, Postgraduateemail@example.com|
|Study Director:||Jian Zhang, Doctor||Xijing Hospital|